A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Study Purpose

The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Participants has provided informed consent before initiation of any study-specific activities/procedures.
  • - Newly diagnosed or relapse of granulomatosis with polyangiitis or microscopic polyangiitis, consistent with Chapel-Hill Consensus Conference definitions (Jennette et al, 2013), where induction treatment with cyclophosphamide or rituximab is needed.
  • - Age >/= 18 years (or >/= legal age within the country if it is older than 18 years).
  • - Positive test for anti-positive antiproteinase 3 or antimyeloperoxidase (current or historic) antibodies.
  • - At least 1 Birmingham Vasculitis Activity Score (BVAS) major item, or at least 3 BVAS nonmajor items, or at least the 2 renal items of proteinuria and hematuria.
  • - eGFR >/= 15 mL/min/1.73 m^2 (using Chronic Kidney Disease Epidemiology Collaboration equations).
Exclusion Criteria.
  • - Alveolar hemorrhage requiring invasive pulmonary ventilation support anticipated to last beyond the screening period of the study.
  • - Any other known multisystem autoimmune disease including eosinophilic granulomatosis with polyangiitis (GPA [Churg-Strauss]), systemic lupus erythematosus, immunoglobulin (Ig) A vasculitis (Henoch-Schönlein), rheumatoid vasculitis, Sjogren's syndrome, anti-glomerular basement membrane disease, or cryoglobulinemic vasculitis.
  • - Any medical condition requiring or expected to require continued use of immunosuppressive therapies, including corticosteroids that may cause confoundment with study assessments and study conclusions.
  • - Received dialysis or plasma exchange within 12 weeks before signing of the informed consent.
  • - Have had a kidney transplant.
  • - Malignancy (except curatively treated nonmelanoma skin cancers, curatively treated cervical carcinoma in situ, or breast ductal carcinoma in situ within the last 5 years before signing the informed consent).
  • - Acute or chronic, active hepatitis B virus or hepatitis C virus, or human immunodeficiency virus infection during screening.
  • - Positive test for active or latent tuberculosis during screening.
  • - White blood cell count < 3500/µL, neutrophil count < 1500/µL, or lymphocyte count < 500/µl.
Note: Complete Blood Count can be repeated once in the screening period per investigator discretion. In this case, eligibility will be determined based on the repeat complete blood count.
  • - Evidence of clinically significant hepatic disease including prior diagnosis of cirrhosis.
  • - Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP) >2.0 times the upper limit of normal (ULN).
  • - Total bilirubin > 1.5 times the ULN.
A participant with documented Gilbert's syndrome with total bilirubin < 2 x ULN may be eligible.
  • - Active infection and/or infection requiring oral or intravenous (IV) anti-infective agents within 4 weeks before signing of the informed consent or completion of oral anti-infective agents within 2 weeks prior to signing informed consent.
  • - History of any clinically significant cardiovascular disease, such as symptomatic congestive heart failure, unstable angina, myocardial infarction or stroke, within 12 weeks before signing of the informed consent.
  • - Received cyclophosphamide (CYC) within 12 weeks before signing the informed consent; if on azathioprine (AZA), mycophenolate, or methotrexate at the time of screening, these drugs must be withdrawn before receiving the CYC or rituximab (RTX).
Note: If induction therapy with cyclophosphamide was started within 1 week before signing the informed consent for the current episode of newly diagnosed or relapse of GPA or MPA, the participant may be eligible, provided no cyclophosphamide was received within 12 weeks before the start of the current induction therapy and if on AZA, mycophenolate, or MTX, these were withdrawn prior to receiving the current induction therapy with cyclophosphamide.
  • - Have been taking an oral daily dose of a glucocorticoid of more than 10 mg prednisone equivalent for more than 6 weeks continuously before signing of the informed consent.
  • - Received RTX or other B-cell depleting therapies within 26 weeks before signing of the informed consent.
Note: If induction therapy with rituximab was started within 1 week before signing the informed consent for the current episode of newly diagnosed or relapse of GPA or MPA, the participant may be eligible, provided no rituximab was received within 26 weeks before the start of the current induction therapy and if on AZA, mycophenolate, or MTX, these were withdrawn prior to receiving the current induction therapy with RTX.
  • - Received any of the following within 12 weeks before signing the informed consent: - antitumor necrosis factor treatment.
  • - abatacept.
  • - alemtuzumab.
  • - IV Ig.
  • - belimumab.
  • - tocilizumab.
  • - Taking a strong or moderate inducer of the cytochrome P450 3A4 (CYP3A4) enzyme unless the strong or moderate CYP3A4 inducer can be changed to an alternative medicine at least 1 week before Day 1.
  • - Received an investigational drug within 30 days or within 5 half-lives (whichever is longer) before signing of the informed consent.
  • - Previously received avacopan without clinical benefit per the Investigator's opinion or received avacopan within 60 days before signing of the informed consent.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT06072482
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 4
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Amgen
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

MD
Principal Investigator Affiliation Amgen
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Czechia, Hungary, Poland, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Study Website: View Trial Website
Arms & Interventions

Arms

Experimental: Group A: Avacopan + Standard of Care (SoC)

Avacopan 30 mg twice daily for 5 years + SoC background immunosuppressive therapy.

Experimental: Group B: Avacopan/Placebo + SoC

Avacopan 30 mg twice daily for 1 year, followed by placebo twice daily for 4 years + SoC background immunosuppressive therapy.

Placebo Comparator: Group C: Placebo + SoC

Placebo twice daily for 5 years + SoC background immunosuppressive therapy.

Interventions

Drug: - Avacopan

Administered orally.

Drug: - Placebo

Administered orally.

Drug: - Standard of Care

All participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Orthopedic Physicians Alaska, Anchorage 5879400, Alaska 5879092

Status

Terminated

Address

Orthopedic Physicians Alaska

Anchorage 5879400, Alaska 5879092, 99508

Scottsdale 5313457, Arizona 5551752

Status

Recruiting

Address

Scottsdale Healthcare at Shea - HonorHealth

Scottsdale 5313457, Arizona 5551752, 85254

Southwest Kidney Institute, Surprise 5316428, Arizona 5551752

Status

Recruiting

Address

Southwest Kidney Institute

Surprise 5316428, Arizona 5551752, 85374

Medvin Clinical Research, Covina 5340175, California 5332921

Status

Recruiting

Address

Medvin Clinical Research

Covina 5340175, California 5332921, 91722

Palo Alto Medical Foundation Fremont, Fremont 5350734, California 5332921

Status

Recruiting

Address

Palo Alto Medical Foundation Fremont

Fremont 5350734, California 5332921, 94538

The Nephrology Group, Fresno 5350937, California 5332921

Status

Recruiting

Address

The Nephrology Group

Fresno 5350937, California 5332921, 93720

Providence Medical Foundation, Fullerton 5351247, California 5332921

Status

Recruiting

Address

Providence Medical Foundation

Fullerton 5351247, California 5332921, 92835

Medvin Clinical Research, Menifee 5372205, California 5332921

Status

Recruiting

Address

Medvin Clinical Research

Menifee 5372205, California 5332921, 92586

Torrance 5403022, California 5332921

Status

Recruiting

Address

Harbor University of California at Los Angeles Medical Center

Torrance 5403022, California 5332921, 90502

University of Colorado, Aurora 5412347, Colorado 5417618

Status

Recruiting

Address

University of Colorado

Aurora 5412347, Colorado 5417618, 80045

Florida Kidney Physicians, Boca Raton 4148411, Florida 4155751

Status

Recruiting

Address

Florida Kidney Physicians

Boca Raton 4148411, Florida 4155751, 33431

Gainesville 4156404, Florida 4155751

Status

Recruiting

Address

Malcom Randall Veterans Affairs Medical Center

Gainesville 4156404, Florida 4155751, 32608

University of South Florida, Tampa 4174757, Florida 4155751

Status

Recruiting

Address

University of South Florida

Tampa 4174757, Florida 4155751, 33606

Emory University, Atlanta 4180439, Georgia 4197000

Status

Recruiting

Address

Emory University

Atlanta 4180439, Georgia 4197000, 30322

Lake Cumberland Rheumatology, New Albany 4262045, Indiana 4921868

Status

Recruiting

Address

Lake Cumberland Rheumatology

New Albany 4262045, Indiana 4921868, 47150

University of Iowa Hospitals and Clinics, Iowa City 4862034, Iowa 4862182

Status

Recruiting

Address

University of Iowa Hospitals and Clinics

Iowa City 4862034, Iowa 4862182, 52242

Dunes Clinical Research LLC, Sioux City 4876523, Iowa 4862182

Status

Recruiting

Address

Dunes Clinical Research LLC

Sioux City 4876523, Iowa 4862182, 51104

University of Kentucky, Lexington 4297983, Kentucky 6254925

Status

Recruiting

Address

University of Kentucky

Lexington 4297983, Kentucky 6254925, 40536

Johns Hopkins Bayview Medical Center, Baltimore 4347778, Maryland 4361885

Status

Recruiting

Address

Johns Hopkins Bayview Medical Center

Baltimore 4347778, Maryland 4361885, 21224

Massachusetts General Hospital, Boston 4930956, Massachusetts 6254926

Status

Recruiting

Address

Massachusetts General Hospital

Boston 4930956, Massachusetts 6254926, 02114

Brigham and Womens Hospital, Boston 4930956, Massachusetts 6254926

Status

Recruiting

Address

Brigham and Womens Hospital

Boston 4930956, Massachusetts 6254926, 02115

Henry Ford Health System, Detroit 4990729, Michigan 5001836

Status

Recruiting

Address

Henry Ford Health System

Detroit 4990729, Michigan 5001836, 48202

University of Minnesota, Minneapolis 5037649, Minnesota 5037779

Status

Recruiting

Address

University of Minnesota

Minneapolis 5037649, Minnesota 5037779, 55414

Mayo Clinic, Rochester 5043473, Minnesota 5037779

Status

Recruiting

Address

Mayo Clinic

Rochester 5043473, Minnesota 5037779, 55905

Renown Rheumatology, Reno 5511077, Nevada 5509151

Status

Recruiting

Address

Renown Rheumatology

Reno 5511077, Nevada 5509151, 89502

Albany 5106834, New York 5128638

Status

Recruiting

Address

New York Nephrology Vasculitis and Glomerular Center

Albany 5106834, New York 5128638, 12209

Northwell Health, Great Neck 5119218, New York 5128638

Status

Recruiting

Address

Northwell Health

Great Neck 5119218, New York 5128638, 11021

Hospital For Special Surgery, New York 5128581, New York 5128638

Status

Recruiting

Address

Hospital For Special Surgery

New York 5128581, New York 5128638, 10021

Greenville 4469160, North Carolina 4482348

Status

Recruiting

Address

East Carolina University Brody Outpatient Center

Greenville 4469160, North Carolina 4482348, 27834

Brookview Hills Research Associates Llc, Winston-Salem 4499612, North Carolina 4482348

Status

Recruiting

Address

Brookview Hills Research Associates Llc

Winston-Salem 4499612, North Carolina 4482348, 27103

Cleveland 5150529, Ohio 5165418

Status

Recruiting

Address

University Hospitals Cleveland Medical Center

Cleveland 5150529, Ohio 5165418, 44106

The Ohio State University, Columbus 4509177, Ohio 5165418

Status

Recruiting

Address

The Ohio State University

Columbus 4509177, Ohio 5165418, 43201

Stat Research, Miamisburg 4518188, Ohio 5165418

Status

Recruiting

Address

Stat Research

Miamisburg 4518188, Ohio 5165418, 45342

Hightower Clinical, Oklahoma City 4544349, Oklahoma 4544379

Status

Recruiting

Address

Hightower Clinical

Oklahoma City 4544349, Oklahoma 4544379, 73114

University of Pennsylvania, Philadelphia 4560349, Pennsylvania 6254927

Status

Recruiting

Address

University of Pennsylvania

Philadelphia 4560349, Pennsylvania 6254927, 19104

Pittsburgh 5206379, Pennsylvania 6254927

Status

Recruiting

Address

Allegheny Health Network Cancer Institute at Mellon Pavilion

Pittsburgh 5206379, Pennsylvania 6254927, 15224

University of Pittsburgh Medical Center, Pittsburgh 5206379, Pennsylvania 6254927

Status

Recruiting

Address

University of Pittsburgh Medical Center

Pittsburgh 5206379, Pennsylvania 6254927, 15261

Nephrology Associates Inc, East Providence 5221931, Rhode Island 5224323

Status

Recruiting

Address

Nephrology Associates Inc

East Providence 5221931, Rhode Island 5224323, 02914

Medical University of South Carolina, Charleston 4574324, South Carolina 4597040

Status

Recruiting

Address

Medical University of South Carolina

Charleston 4574324, South Carolina 4597040, 29425

West Tennessee Research Institute, Jackson 4632595, Tennessee 4662168

Status

Recruiting

Address

West Tennessee Research Institute

Jackson 4632595, Tennessee 4662168, 38305

Vanderbilt University Medical Center, Nashville 4644585, Tennessee 4662168

Status

Recruiting

Address

Vanderbilt University Medical Center

Nashville 4644585, Tennessee 4662168, 37232

Dallas 4684888, Texas 4736286

Status

Recruiting

Address

Renal Disease Research Institute - Landry Office

Dallas 4684888, Texas 4736286, 75204

Scott and White Memorial Hospital, Temple 4735966, Texas 4736286

Status

Recruiting

Address

Scott and White Memorial Hospital

Temple 4735966, Texas 4736286, 76502

Fairfax 4758023, Virginia 6254928

Status

Recruiting

Address

Nephrology Associates of Northern Virginia Inc

Fairfax 4758023, Virginia 6254928, 22033

Virginia Mason Medical Center, Seattle 5809844, Washington 5815135

Status

Recruiting

Address

Virginia Mason Medical Center

Seattle 5809844, Washington 5815135, 98101

Rheumatology and Pulmonary Clinic, Beckley 4798308, West Virginia 4826850

Status

Recruiting

Address

Rheumatology and Pulmonary Clinic

Beckley 4798308, West Virginia 4826850, 25801

International Sites

Fakultni nemocnice Olomouc, Olomouc 3069011, Czechia

Status

Recruiting

Address

Fakultni nemocnice Olomouc

Olomouc 3069011, , 779 00

Fakultni nemocnice Ostrava, Ostrava - Poruba, Czechia

Status

Recruiting

Address

Fakultni nemocnice Ostrava

Ostrava - Poruba, , 708 52

Fakultni nemocnice Kralovske Vinohrady, Prague 3067696, Czechia

Status

Recruiting

Address

Fakultni nemocnice Kralovske Vinohrady

Prague 3067696, , 100 34

Revmatologicky ustav, Prague 3067696, Czechia

Status

Recruiting

Address

Revmatologicky ustav

Prague 3067696, , 128 00

Vseobecna fakultni nemocnice v Praze, Prague 3067696, Czechia

Status

Recruiting

Address

Vseobecna fakultni nemocnice v Praze

Prague 3067696, , 128 08

Debreceni Egyetem Klinikai Kozpont, Debrecen 721472, Hungary

Status

Recruiting

Address

Debreceni Egyetem Klinikai Kozpont

Debrecen 721472, , 4032

Pecsi Tudomanyegyetem Klinikai Kozpont, Pécs 3046526, Hungary

Status

Recruiting

Address

Pecsi Tudomanyegyetem Klinikai Kozpont

Pécs 3046526, , 7632

Lodz 3093133, Poland

Status

Recruiting

Address

SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im Norberta Barlickiego Uniwersytetu Medycznego w Lodzi

Lodz 3093133, , 90-153

Lodz 3093133, Poland

Status

Recruiting

Address

Spzoz Centralny Szpital Kliniczny Umed w Lodzi

Lodz 3093133, , 92-213

Warsaw 756135, Poland

Status

Recruiting

Address

Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher

Warsaw 756135, , 02-637

Warsaw 756135, Poland

Status

Recruiting

Address

Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy Centralny Szpital Kliniczny Mon

Warsaw 756135, , 04-141